Formuepleje A S Purchases Shares of 1,855 IDEXX Laboratories, Inc. $IDXX

Formuepleje A S purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 2nd quarter, HoldingsChannel reports. The fund purchased 1,855 shares of the company’s stock, valued at approximately $977,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IDXX. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in IDEXX Laboratories during the 2nd quarter worth approximately $48,547,000. California State Teachers Retirement System raised its stake in IDEXX Laboratories by 50,115.1% during the second quarter. California State Teachers Retirement System now owns 61,590,848 shares of the company’s stock worth $32,423,886,000 after buying an additional 61,468,194 shares during the last quarter. Saudi Central Bank lifted its holdings in IDEXX Laboratories by 88.7% in the second quarter. Saudi Central Bank now owns 5,560 shares of the company’s stock valued at $2,927,000 after buying an additional 2,613 shares during the period. AlphaGrep UK Ltd acquired a new position in IDEXX Laboratories in the second quarter valued at $1,385,000. Finally, Maloon Powers Pitre Higgins & Dennehy LLC bought a new stake in IDEXX Laboratories during the second quarter valued at $303,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $535.38 on Monday. IDEXX Laboratories, Inc. has a one year low of $518.55 and a one year high of $769.98. The company has a market cap of $42.18 billion, a PE ratio of 37.65, a P/E/G ratio of 2.86 and a beta of 1.54. The stock has a 50-day moving average of $558.27 and a 200-day moving average of $570.05. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The business had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the prior year, the business earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on IDXX shares. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. UBS Group lifted their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Citigroup increased their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. Finally, Barclays lowered their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $747.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.